Atomoxetine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Atomoxetine: Specific developmental disorder
One-Sentence Summary
Atomoxetine is a selective norepinephrine reuptake inhibitor marketed in Australia as an oral capsule. The TxGNN model predicts it may be useful for specific developmental disorder. No clinical trials and no studies directly testing this disease were found, so the evidence level is L5 (model prediction only).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Specific developmental disorder |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Atomoxetine blocks the reuptake of norepinephrine. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description rests on the drug’s known drug class.
Specific developmental disorders, such as learning disabilities, often occur alongside the neurodevelopmental condition for which atomoxetine is already used. Any benefit would most plausibly come from improved attention and executive function. It would not come from a direct effect on the underlying learning deficit.
The publications linked to this prediction study the drug’s established use, including in children with autism. None of them tests atomoxetine in a specific developmental disorder. The high model score therefore reflects association patterns, not demonstrated efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of the publications below directly studies atomoxetine in specific developmental disorder. They concern the drug’s established use and related comorbid conditions.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39701638 | 2025 | Systematic review / network meta-analysis | The Lancet Psychiatry | Compared the benefits and harms of drug, psychological and neurostimulatory interventions in adults for the drug’s established use |
| 30653855 | 2019 | Systematic review / meta-analysis | Autism Research | Three placebo-controlled RCTs (241 children) examined atomoxetine for attention-related symptoms in children with autism |
| 27721971 | 2016 | Review | Therapeutic Advances in Psychopharmacology | Reviewed atomoxetine efficacy in patients with common comorbid conditions across age groups |
| 35485452 | 2022 | Cohort (retrospective) | Neuropsychopharmacology Reports | Identified patient factors associated with atomoxetine response in adults |
| 33012168 | 2021 | Cohort | Clinical EEG and Neuroscience | Discussed quantitative EEG in childhood attention problems and learning disabilities; not a drug efficacy study |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 9092M | APO-Atomoxetine | Capsule 10 mg (as hydrochloride) | Not stated in the data compiled for this report |
Safety Considerations
Drug interactions (100 interacting drugs recorded; main examples):
- Major: cisapride, dolasetron
- Moderate: bupropion, clarithromycin, cimetidine, famotidine, epinephrine, ephedrine, eliglustat, fenfluramine, granisetron, loperamide, isometheptene
For warnings, contraindications and other safety information, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The model score is very high, but no clinical trial and no publication directly studies atomoxetine in specific developmental disorder. The evidence level is therefore L5. Any plausible benefit would be indirect, through attention and executive function, and has not been demonstrated.
To proceed, the following is needed:
- Studies that directly test atomoxetine in specific developmental disorder, with outcomes beyond attention symptoms
- Detailed mechanism-of-action data to support a mechanistic link
- Review of the TGA-approved Product Information (PI) for warnings, contraindications and interactions
- A defined target population and safety monitoring plan before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.